In a report published Monday, Morgan Stanley reiterated its Overweight rating on Gilead Sciences (NASDAQ: GILD ). Morgan Stanley noted, “Additional Phase III data for 7977/sofosbuvir are as expected and continue to support a best in class profile and a multi-billion dollar opportunity for Gilead with a likely launch in